Received Jul 7, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 3 | — | LA |
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | IM / LA |
skin on her whole body has turned to leather; This non-serious case was reported by a consumer via call center representative and described the occurrence of skin texture abnormal in a 72-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) suspension for injection for prophylaxis. Co-suspect products included Elasomeran (Moderna COVID-19 vaccine) for prophylaxis. On 16-OCT-2023, the patient received Arexvy (intramuscular, left arm) .5 ml and the 3rd dose of Moderna COVID-19 vaccine (left arm). On an unknown date, an unknown time after receiving Arexvy and an unknown time after receiving Moderna COVID-19 vaccine, the patient experienced skin texture abnormal (Verbatim: skin on her whole body has turned to leather).The outcome of the skin texture abnormal was not resolved. It was unknown if the reporter considered the skin texture abnormal to be related to Arexvy. Additional Information: GSK Receipt Date: 01-JUL-2026 The patient self-reported this case for herself. It was unknown if the reporter considered the skin texture abnormal to be related to Moderna COVID-19 vaccine. The batch number was not provided upon follow up with the reporter.